Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 2/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | CPA3 | P15088 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515818 | 0.89 | POLB (0.33) | FOLH1POLBALDH1A1MMP1MMP2 | |
| SCHEMBL3237667 | 0.77 | FOLH1 (0.43) | FOLH1POLBALDH1A1MMP1MMP2 | |
| SCHEMBL4100218 | 0.73 | EGLN1 (0.47) | FOLH1TDP1 | |
| SCHEMBL10259513 | 0.72 | FOLH1 (0.46) | FOLH1CPA1CPB1CPA3CPB2 | |
| SCHEMBL5369808 | 0.72 | FOLH1 (0.50) | FOLH1CPA1CPB1CPA3CPB2 | |
| Tricarballylic Acid SCHEMBL1821947 | 0.71 | FOLH1 (0.65) | FOLH1CPA1CPB1CPA3CPB2 | |
| Tricarballylic Acid SCHEMBL34866 | 0.71 | FOLH1 (0.65) | FOLH1CPA1CPB1CPA3CPB2 | |
| SCHEMBL5051962 | 0.70 | FOLH1 (0.48) | FOLH1CPA1CPB1CPA3CPB2 | |
| SCHEMBL7767241 | 0.69 | MGAM (0.44) | FOLH1ALDH1A1CPA1CPB1CPA3 | |
| SCHEMBL28186314 | 0.69 | FOLH1 (0.46) | FOLH1CPA1CPB1CPA3CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770442-B2 | Self-assembling amphiphilic polymers as anti-cancer agents | ALLEXCEL INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770442-B2 | Self-assembling amphiphilic polymers as anti-cancer agents | ALLEXCEL INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL, INC. | 2010-01-14 | — | — | US | disclosed |
| WO-2009011702-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS | ALLEXCEL, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008091246-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | PICALM, CLTA, HAVCR2 | FOLH1 3186/4885POLB 1162/4885ALDH1A1 4248/4885 |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | CD44, EPCAM, EGFR | FOLH1 1516/4885POLB 3287/4885ALDH1A1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.